Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,349 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Gastrointestinal Neoplasm Clear all
Terminated Phase 2 Interventional

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

NCT05576896
View directory record Official record
Conditions
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV
Interventions
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Active, not recruiting Phase 1 Interventional

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273
View directory record Official record
Conditions
Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Hepatocellular Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Pleural Neoplasm, Malignant Skin Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Thymus Neoplasm, Neuroendocrine Neoplasm, Thyroid Gland Carcinoma, Urothelial Carcinoma, Cancer of Unknown Primary Site
Interventions
Computed Tomography, Gallium Ga 68 FAPi-46, Positron Emission Tomography, 18F-FDG
Procedure · Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329
View directory record Official record
Conditions
Crohn's Disease, IBD, Colitis, Inflammatory Bowel Disease
Interventions
Group 2 ustekinumab 130 mg, Group 3: ustekinumab approximately 6 mg/kg, Group 1: Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
67
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 64 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

NCT02711137
View directory record Official record
Conditions
Solid Tumors
Interventions
INCB057643, Gemcitabine, Paclitaxel, Rucaparib, Abiraterone, Ruxolitinib, Azacitidine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction

NCT06096688
View directory record Official record
Conditions
Colorectal Cancer, Endometrial Cancer, Hereditary Cancer Syndromes
Interventions
Not listed
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1,120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

NCT03535727
View directory record Official record
Conditions
Adenocarcinoma, Pancreatic Neoplasms, Neoplasm, Glandular, Neoplasms, Neoplasms Pancreatic, Digestive System Neoplasm, Endocrine Gland Neoplasms, Digestive System Disease, Pancreatic Diseases, Endocrine System Diseases
Interventions
Nab-paclitaxel, Gemcitabine, Capecitabine, Cisplatin, Irinotecan
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 76 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 2 Interventional Results available

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

NCT04515394
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Tepotinib, Cetuximab
Drug · Biological
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • La Jolla, California • Santa Monica, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia

NCT01164722
View directory record Official record
Conditions
Anal Cancer, Neoplasm of Uncertain Malignant Potential, Nonneoplastic Condition, Precancerous Condition
Interventions
clinical observation, infrared photocoagulation therapy
Other · Device
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
27 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 1 Interventional

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

NCT01238042
View directory record Official record
Conditions
Barrett's Esophagus, CIS, HGD
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2014 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated No phase listed Observational

Effect of Antireflux Therapy on the Expression of Genes in Patients With GERD

NCT00624546
View directory record Official record
Conditions
GERD, Gastroesophageal Reflux
Interventions
Prevacid Solutabs, Antireflux surgery
Drug · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2015 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 2 Interventional

Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

NCT00103103
View directory record Official record
Conditions
Gastric Cancer
Interventions
bortezomib, fluorouracil, leucovorin calcium
Drug
Lead sponsor
California Cancer Consortium
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
5
States / cities
Duarte, California • Los Angeles, California • Pasadena, California + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2010 · Synced Jul 22, 2026, 10:00 AM EDT
Active, not recruiting Phase 1 Interventional

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

NCT04605731
View directory record Official record
Conditions
BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Interventions
Durvalumab, Tremelimumab
Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 3 Interventional Results available

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

NCT03654729
View directory record Official record
Conditions
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Interventions
Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg), Placebo
Drug
Lead sponsor
Egetis Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jul 22, 2026, 10:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Guilford Genomic Medicine Initiative (GGMI)

NCT01372553
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colon Cancer, Thrombophilia
Interventions
Not listed
Lead sponsor
The Moses H. Cone Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
1,184 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

NCT00305188
View directory record Official record
Conditions
Metastases, Colorectal Neoplasms, Colorectal Carcinoma
Interventions
Xaliproden (SR57746A), Placebo, Oxaliplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Jul 22, 2026, 10:00 AM EDT
Terminated Phase 3 Interventional Results available

Trial of a Sustained Release Methylphenidate in the Treatment of Fatigue in Cancer Patients

NCT00516269
View directory record Official record
Conditions
Breast Cancer, Fatigue, Gastrointestinal Cancer
Interventions
Methylphenidate, Placebo
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Not applicable Interventional

Diet Education Program for Stage I-IV Colorectal Cancer Survivors

NCT04597151
View directory record Official record
Conditions
Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
Interventions
Dietary Intervention
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2023 · Synced Jul 22, 2026, 10:00 AM EDT
Active, not recruiting Phase 3 Interventional

Multi-Center Study of the Effects of Simvastatin on Hepatic Decompensation and Death in Subjects Presenting With High-Risk Compensated Cirrhosis

NCT03654053
View directory record Official record
Conditions
Cirrhosis
Interventions
Placebo Oral Tablet, Simvastatin 40mg
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
11
States / cities
San Francisco, California • West Haven, Connecticut • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Recruiting No phase listed Observational

Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections

NCT06179459
View directory record Official record
Conditions
Acute Pancreatitis, Pancreatic Pseudocyst, Pancreatic Necrosis
Interventions
Endoscopic management of pancreatic fluid collections
Procedure
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Completed No phase listed Observational

Genetic Analysis to Evaluate the Racial Difference in the Outcome of Patients With Colon Cancer

NCT01479894
View directory record Official record
Conditions
Colon Cancer
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Jul 22, 2026, 10:00 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)

NCT07585266
View directory record Official record
Conditions
Gastrointestinal Stromal Neoplasms
Interventions
Velzatinib, Imatinib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional

Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer

NCT01360853
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
ON 01910.Na, Gemcitabine
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
30
States / cities
La Jolla, California • Palm Springs, California • Salinas, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2016 · Synced Jul 22, 2026, 10:00 AM EDT
Completed Phase 3 Interventional Results available

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

NCT00471146
View directory record Official record
Conditions
Carcinoma, Pancreatic Ductal
Interventions
AG-013736, Gemcitabine, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
77
States / cities
Antioch, California • Corona, California • Glendora, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2012 · Synced Jul 22, 2026, 10:00 AM EDT